Algeta initiates new R&D program to investigate a Targeted Thorium Conjugate (TTC) against hematological cancers

17-Aug-2012 - Norway

Algeta ASA announced it has initiated a new research and development program aimed at investigating the effect of a novel Targeted thorium Conjugate (TTC) on hematological cancers.

The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to the alpha-particle emitter thorium-227 (Th-227).

This new program represents Algeta’s fourth TTC program and as part of the project the Company has entered into a fee-for-service agreement with Cobra Biologics, which will manufacture the antibody in its GMP-approved facility in Södertälje, Sweden. Algeta has already demonstrated it can chelate Th-227 to this antibody in exploratory studies.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous